Selected matrix metalloproteinases activity and hypertension-mediated organ damage in relation to uric acid serum level

Cardiol J. 2021;28(6):905-913. doi: 10.5603/CJ.a2019.0033. Epub 2019 Apr 17.

Abstract

Background: Atherosclerosis is as a systemic inflammatory disease associated with the activationof many mediators, including matrix metalloproteinases (MMPs), and may be amplified by abnormal high serum uric acid (UA) concentration (hyperuricemia, HU). The aim of the study was to determine the relationship between serum UA concentration and activity of MMPs and their correlation with the hypertension-mediated organ damage (HMOD) intensity.

Methods: One hundred and nine patients untreated with antihypertensive, hypolipemic or uratelowering drugs with diagnosed stage 1-2 essential hypertension were included in this study. In all participants blood pressure (BP) was measured, carotid-femoral pulse wave velocity (PWV), intima-media thickness (IMT), echocardiography and blood tests including UA, lipids and serum concentrations of MMPs (1, 2, 3, 9) were observed. The participants were divided into hyper- and normuricemic groups.

Results: Uric acid concentration in the whole study group positively correlated with some HMOD parameters (IMT, PWV, left ventricular mass index, left atrial dimension). Among the studied metalloproteinases only MMP-3 activity positively correlated with serum UA concentration independently of age, body mass index and serum lipids (R2 = 0.11, p = 0.048). Multivariate regression analysis showed positive association between IMT and BP, UA concentration and MMP-3 activity, independently of waist circumference and serum lipids (R2 = 0.328, p < 0.002). Patients with HU were characterized by higher activity of MMP-3 than those without (19.41 [14.45; 21.74] vs. 13.98 [9.52; 18.97] ng/mL, p = 0.016).

Conclusions: The present results may support the thesis that UA and the increased by UA activity of MMPs may take part in the development of HMOD, especially IMT.

Keywords: arterial hypertension; hyperuricemia; matrix metalloproteinases; metabolic syndrome; uric acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carotid Intima-Media Thickness
  • Humans
  • Hypertension* / complications
  • Hypertension* / diagnosis
  • Lipids
  • Matrix Metalloproteinase 3
  • Pulse Wave Analysis
  • Risk Factors
  • Uric Acid
  • Vascular Stiffness* / physiology

Substances

  • Lipids
  • Uric Acid
  • Matrix Metalloproteinase 3